PATENT CLAIM ANALYSIS

Application Number: 15755270
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-09
Patent Classification: ["514", "253010"]

Abstract:
The present disclosure relates to pharmaceutical combinations comprising a cyclin dependent kinase 4/6 (CDK4/6) inhibitor compound, (b) a B-Raf inhibitor compound, and optionally (c) an alpha-isoform specific phosphatidylinositol 3-kinase (PI3K) inhibitor compound, for the treatment or prevention of cancer, as well as related pharmaceutical compositions, uses, and methods of treatment or prevention of cancer.

Claim (Index 25):
The pharmaceutical composition of  claim 24 , further comprising a third compound having the structure of Formula (III): or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 88.0
- Lexical Diversity: 1.56818
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15755122', '14893746', '13499779', '15755140', '14197421']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7656193656593732
- 35 USC 102 Novelty (BERT): 0.5690200464874101
- Combined Prediction Score: 0.7459594337421769
- Mean Citation Score: 380.46978200000007
- Max Citation Score: 519.1352
- Similarity Product: 313.64960864973074

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test